Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator
- PMID: 35322450
- PMCID: PMC9544666
- DOI: 10.1111/bcp.15326
Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator
Abstract
Aims: This study aimed to assess the impact of a National Reporting Indicator (NRI) on rates of reporting of suspected adverse drug reactions using the Yellow Card scheme following the introduction of the NRI in Wales (UK) in April 2014.
Methods: Yellow Card reporting data for general practitioners and other reporting groups in Wales and England for the financial years 2014-15 (study period 1) and 2015-16 (study period 2) were obtained from the Medicines and Healthcare Products Regulatory Agency and compared with those for 2013-14 (pre-NRI control period).
Results: The numbers of Yellow Cards submitted by general practitioners in Wales were 271, 665 and 870 in the control period, study period 1 and study period 2, respectively. This is equivalent to an increase of 145% in study period 1 and 221% in study period 2 compared with the 12-month control period (2013-14). Corresponding increases in England were 17% and 37%, respectively (P < .001 chi-squared test). The numbers of Yellow Cards submitted by other groups in Wales were 906, 795 and 947 in each of the study periods.
Conclusions: Introduction of the NRI corresponded with a significant increase in the number of Yellow Cards submitted by general practitioners in Wales. General practitioner reporting rates continued to increase year on year through to 2018-19 with the NRI still in place. No concomitant change was found in reporting rates by other groups in the health boards in Wales.
Keywords: National Reporting Indicator; adverse drug reaction reports; incentives.
© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Figures
References
-
- Medicines and Healthcare Products Regulatory Agency (2015, last updated 2021) . The Yellow Card scheme: guidance for healthcare professionals, patients, and the public. https://www.gov.uk/guidance/the‐yellow‐card‐scheme‐guidance‐for‐healthca... (Accessed 30/01/2021).
-
- Houghton J, Woods F, Richens A, Routledge PA. The Welsh Adverse Drug Reactions Scheme: ten years' experience of a regional monitoring centre. Adv React Acute Pois Rev. 1996;15:93‐107. - PubMed
-
- Welsh Government . (2020). Statistical First Release. Prescriptions in Wales 2019–2020. https://gov.wales/sites/default/files/statistics‐and‐research/2020‐09/pr... (Accessed 19/01/2021).
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
